Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | IAPP | P10997 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PELI1 | Q96FA3 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3464491 | 0.88 | AKR1C3 (0.35) | AKR1C3PTGS2PTGS1KDM4ERAB9A | |
| SCHEMBL3465316 | 0.87 | AKR1C3 (0.35) | AKR1C3PTGS2PTGS1KDM4ERAB9A | |
| SCHEMBL11669530 | 0.83 | PTGS2 (0.36) | AKR1C3PTGS2PTGS1KDM4ERAB9A | |
| SCHEMBL27827229 | 0.82 | ALDH1A1 (0.40) | AKR1C3PTGS2PTGS1KDM4ERAB9A | |
| SCHEMBL3465167 | 0.81 | SMN1; SMN2 (0.49) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL24038842 | 0.79 | PTGS2 (0.55) | AKR1C3PTGS2PTGS1KDM4ERAB9A | |
| SCHEMBL30456577 | 0.79 | PTGS2 (0.55) | AKR1C3PTGS2PTGS1KDM4ERAB9A | |
| SCHEMBL3466133 | 0.78 | ALDH1A1 (0.41) | PTGS2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3465397 | 0.74 | ALDH1A1 (0.40) | AKR1C3ALDH1A1LMNAHSD17B10 | |
| SCHEMBL30745893 | 0.73 | CA2 (0.47) | KDM4EALDH1A1LMNAHPGDHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | AKR1C3 686/4885PTGS2 2200/4885PTGS1 737/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | AKR1C3 173/4885PTGS2 367/4885PTGS1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.